BICO Group AB (CELLINK)
BICO Group AB, through its flagship brand CELLINK, is a dominant global player in 3D bioprinting, offering a diversified portfolio of bioprinters, bioinks, and software. CELLINK pioneered the first universal bioink in 2016, and the company continues to drive innovation to reduce organ shortages and accelerate drug development. Their technology encompasses extrusion and light-based bioprinters like the BIO X, BIO X6, and LUMEN X, which are used by researchers for 3D cell cultures, tissue engineering, and drug screening. BICO focuses on providing high-tech equipment and materials to create living, functional tissues and organ-on-a-chip models. Their commitment extends to automation, with products like DNA Studio 4 Vault software, to improve scalability for clinical applications, reinforcing their position at the forefront of regenerative medicine and personalized medicine.
Latest Market Research Report on 3D Bioprinting Download PDF Brochure Now
3D Systems, Inc.
3D Systems, Inc. holds a strong position in the 3D bioprinting market, leveraging its expertise in additive manufacturing to develop solutions for regenerative medicine. The company’s strategy involves a strong product portfolio of 3D bioprinters, bioinks, and software, exemplified by the acquisition of ALLEVI. A key focus is on printing complex, vascularized tissues essential for organ manufacturing through its “Print to Perfusion” process, developed in partnership with United Therapeutics Corporation. Furthermore, 3D Systems established a new biotech firm, Systemic Bio, to accelerate drug discovery by creating highly precise vascularized organ models using its production-level bioprinting technology. By investing in manufacturing capabilities and supply chain infrastructure, 3D Systems is working to improve access and affordability, driving the clinical translation of bioprinting solutions.
Organovo Holdings Inc. (VivoSim Labs)
Organovo Holdings Inc., now operating as VivoSim Labs, is a key player in bioprinting and tissue engineering, focused on developing therapeutics and drug profiling capabilities. The company utilizes its NovoGen bioprinting platform to build multicellular, scaffold-free human tissues that mimic critical aspects of diseases. Organovo has notably shifted its focus toward therapeutic applications, particularly for liver tissues. Their 3D bioprinted human tissue models, like the NAMkind 3D liver and intestinal toxicology models, are used to de-risk drug programs and select compounds by detecting true human toxicity signals early, reducing reliance on animal models. Recent developments, such as the acquisition of their FXR program by Eli Lilly, demonstrate the clinical relevance of their 3D bioprinted models in guiding therapeutic strategies for conditions like ulcerative colitis.
Collplant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd. is a major player in regenerative medicine, distinguished by its unique plant-based collagen bioink, known as rhCollagen. This bioink is highly regarded for its biocompatibility and versatility, making it ideal for 3D bioprinting applications, including the creation of tissues and organs. The company is actively involved in a high-profile collaboration with United Therapeutics to develop bioprinted lungs for transplantation, addressing the critical shortage of donor organs. In addition to organ printing, CollPlant is expanding its medical footprint by working on dermal fillers and breast implants. Their focus on scalable manufacturing processes for their proprietary bioink and exploring new markets like orthopedics and wound care solidifies their innovative standing in the 3D bioprinting landscape.
Aspect Biosystems Ltd.
Aspect Biosystems Ltd. is a leader in 3D bioprinting innovation, particularly known for creating functional living tissues for drug research and regenerative medicine. The Canadian firm fuses microfluidics with an AI-driven platform technology to replicate human tissues with high fidelity. Their technology aims to create bioprinted tissue therapeutics, as demonstrated by a collaboration, development, and licensing deal with Novo Nordisk. Aspect Biosystems’ focus on functional tissue engineering allows for the creation of complex, patient-relevant tissue models that accelerate drug discovery and the development of regenerative therapies. Recent significant funding and partnerships underscore their role in advancing bioprinting capabilities toward clinical applications.
Nano 3D Biosciences, Inc.
Nano 3D Biosciences is a key player advancing 3D bioprinting through its innovative magnetic cell aggregation technology. Their core technology involves magnetizing cells and using magnetic forces to quickly aggregate them into 3D tissue-like models. This novel strategy promotes scalability and physiological relevance, which is crucial for creating human tissue models that closely resemble natural tissue environments for study and medication development. By using magnetic 3D bioprinting, the company supports high-throughput screening and disease modeling. Nano 3D Biosciences offers products and services centered around this unique technology, playing an essential role in driving the bioprinting industry’s expansion and the advancement of personalized medicine.
3D Bioprinting Solutions
3D Bioprinting Solutions is an innovative Russian biotech company focused on developing scaffold-free bioprinting technologies and bioinks. They are pioneers in this field, having famously verified their technology through ground-breaking space tests, including successfully bioprinting human cartilage tissue aboard the International Space Station with their OrganAut 3D bioprinter. Their approach enables the printing of living tissues with high precision using single tissue spheroids, eliminating the need for conventional scaffolds. The company’s main focus is on organ fabrication and regenerative medicine technology, which enhances their position in the global market by advancing drug research and personalized therapy, specializing in applications for preclinical models, disease modeling, and organ transplantation.
Regemat 3D S.L.
Regemat 3D S.L. is a prominent biotechnology business based in Spain, specializing in cutting-edge tissue engineering and 3D bioprinting technologies. Established by bioprinting pioneers, Regemat integrates biomaterials, sophisticated bioreactors, and customizable 3D bioprinters into a single platform. Their technology goes beyond simple scaffold printing to produce living, functional tissues by creating intricate, cell-packed scaffolds which are then stimulated by controlled physical forces. This enables the development of physiologically significant tissues for research. The company actively supports the scientific community through international research collaborations, providing customized lab setups, training programs, and ongoing technical assistance, reinforcing its commitment to advancing tissue engineering applications.
Biobots
Biobots has democratized 3D bioprinting by offering affordable, easy-to-use printers capable of producing intricate live tissues for research and drug development. Their technology increases accessibility to bioprinting, particularly for academic and smaller research labs, which in turn accelerates the nascent 3D bioprinting sector. Biobots’ 3D bioprinters create precise, living cell tissues layer by layer by combining visible blue light curing with sophisticated extrusion-based techniques. This method supports the development of complex biological structures that resemble genuine tissue environments, featuring multiple cell types and vasculature. By developing user-friendly solutions, Biobots plays a key role in enabling customized treatment and improving the clinical relevance of bioprinted models.
Prellis Biologics
Prellis Biologics specializes in printing vascularized tissue models, a critical hurdle in drug discovery and regenerative medicine. Their proprietary holographic printing technology is key to creating complex, functional tissues at a high resolution, significantly advancing the development of human organ models. The company has made notable progress in creating miniaturized lymph node structures, which are vital for immunotherapy research as they allow for better *in vitro* study of immune responses. Prellis is focused on scalable solutions for printing microvasculature to improve the integration of bioprinted tissues into live systems, positioning them as an innovative leader for developing complex organ models for drug testing and eventual regenerative medicine applications.
Latest Market Research Report on 3D Bioprinting Download PDF Brochure Now